Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Koval?ík, 19, of Dulovce, Slovakia, ...

Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.

The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the ...

Genetic testing company 23andMe had 15 million consumers who turned to them to learn more about their ancestry and understand their disposition to diseases.

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a ...

Analysts maintain a generally positive outlook on Regeneron’s future prospects, despite the near-term challenges. The consensus view suggests ... provide a clearer picture of investment ...

Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) ...